{"id":"gzr4-injection","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by blocking the action of glucagon, a hormone that raises blood glucose levels, thereby lowering blood glucose levels in patients with type 2 diabetes.","oneSentence":"GZR4 Injection is a glucagon receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:14:45.221Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT07193147","phase":"PHASE1","title":"Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-10-20","conditions":"Diabetes","enrollment":36},{"nctId":"NCT07146347","phase":"PHASE1","title":"Comparison Study of Insulin GZR4 With Insulin Degludec","status":"RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2025-08-15","conditions":"Type 2 Diabetes","enrollment":14},{"nctId":"NCT06974487","phase":"PHASE1","title":"A Phase I Study to Evaluate the PK and PD Profiles of GZR102 Injection Versus GZR4 Injection and GZR18 Injection Given Separately in Chinese Adult Overweight Subjects","status":"NOT_YET_RECRUITING","sponsor":"Gan & Lee Pharmaceuticals.","startDate":"2025-05-08","conditions":"Type 2 Diabetes","enrollment":30},{"nctId":"NCT06202079","phase":"PHASE2","title":"A Trial Comparing the Efficacy and Safety of GZR4 Injection Versus Insulin Degludec in Subjects with Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2023-08-11","conditions":"Diabetes Mellitus, Type 2","enrollment":179},{"nctId":"NCT06547502","phase":"PHASE1","title":"Pharmacokinetics and Safety Profile of a Single Dose GZR4 in Subjects with Renal Impairment","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2024-07-03","conditions":"Diabetes","enrollment":16},{"nctId":"NCT06548906","phase":"PHASE1","title":"A Study of GZR4 Injection at Different Injection Sites","status":"RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2024-05-08","conditions":"Healthy Subjects","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Degludec","Icodec"],"phase":"phase_3","status":"active","brandName":"GZR4 Injection","genericName":"GZR4 Injection","companyName":"Gan and Lee Pharmaceuticals, USA","companyId":"gan-and-lee-pharmaceuticals-usa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GZR4 Injection is a glucagon receptor antagonist. Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}